H1B Salary Data

Home › Employers › Amberstone Biosciences Inc

Amberstone Biosciences Inc: H-1B salaries and sponsorship

Amberstone Biosciences Inc filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $130,000.

Applications (LCAs)4
Certified4
Employer addressIrvine, CA
H-1B dependent employerNo
Median offered salary$130,000
Middle half of salaries$130,000–$130,000
10th–90th percentile$130,000–$130,000

Does Amberstone Biosciences Inc sponsor H-1B visas?

Amberstone Biosciences Inc filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 23, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Project Manager3$130,000
Cell Biologist1—

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20243$130,000
FY20251$130,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Project Manager$130,000–$150,000
Level II
Irvine, CAJun 23, 2025Aug 28, 2025Certified
Project Manager$130,000–$150,000
Level II
Irvine, CAMay 13, 2024Aug 28, 2024Certified
Cell Biologist$60,320–$72,800
part-time · Level I
Irvine, CAApr 16, 2024Sep 29, 2024Certified
Project Manager$130,000–$150,000
Level II
Irvine, CAApr 16, 2024Aug 28, 2024Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).